|
49 Companies |
|
64 Products |
|
64 Products |
|
51 Mechanisms of Action |
|
1 Trial |
|
275 News |
|
| «123456» |
- | paclitaxel / Generic mfg.
Trial completion, Metastases: Safety and Efficacy of S-8184 in Treatment of Locally Advanced, Metastatic, or Recurrent TCC of the Urothelium (clinicaltrials.gov) - Feb 27, 2016
P2, N=27, Completed, Sponsor: OncoGenex Technologies
No longer recruiting --> Completed
- | mocetinostat (MGCD0103) / Otsuka, BMS
Enrollment closed, Metastases: Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes (clinicaltrials.gov) - Feb 18, 2016
P2, N=17, Active, not recruiting, Sponsor: Mirati Therapeutics Inc.
No longer recruiting --> Completed Recruiting --> Active, not recruiting
- cabazitaxel / Generic mfg.
Trial primary completion date: Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy (clinicaltrials.gov) - Feb 11, 2016
P2, N=33, Active, not recruiting, Sponsor: Thomas Jefferson University
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2015 --> Aug 2016
- Votrient (pazopanib) / Novartis, BeiGene
Enrollment change, Trial termination, Trial primary completion date, Metastases: Gemcitabine and Pazopanib in Chemotherapy Na (clinicaltrials.gov) - Feb 4, 2016
P2, N=2, Terminated, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Dec 2015 --> Aug 2016 N=45 --> 2 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2016 --> Feb 2016; Safety reasons
- | Adstiladrin (nadofaragene firadenovec-vncg) / Ferring
Trial completion: Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer (clinicaltrials.gov) - Feb 3, 2016
P2, N=40, Completed, Sponsor: FKD Therapies Oy
N=45 --> 2 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2016 --> Feb 2016; Safety reasons Active, not recruiting --> Completed
- Trial completion: Phase II Trial of Concurrent Administration of Intravesical BCG & Interferon in the Treatment and Prevention of Recurrence of Superficial Transitional Carcinoma of the Urinary Bladder (clinicaltrials.gov) - Dec 17, 2015
P2, N=10, Completed, Sponsor: King Faisal Specialist Hospital & Research Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- sunitinib / Generic mfg.
Enrollment change, Metastases: Trial of Maintenance SU011248 Versus Placebo Post Chemotherapy Patients With Advanced Urothelial Carcinoma (clinicaltrials.gov) - Dec 15, 2015
P2, N=1, Completed, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Active, not recruiting --> Completed N=10 --> 1
- |||| Javlor (vinflunine) / Pierre Fabre
Trial completion, Trial primary completion date, Metastases: JASINT1: JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin (clinicaltrials.gov) - Dec 9, 2015
P2, N=69, Completed, Sponsor: Pierre Fabre Medicament
N=10 --> 1 Active, not recruiting --> Completed | Trial primary completion date: Dec 2012 --> Oct 2013
- valrubicin / Generic mfg.
Trial primary completion date: Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma (clinicaltrials.gov) - Dec 6, 2015
P1, N=4, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Active, not recruiting --> Completed | Trial primary completion date: Dec 2012 --> Oct 2013 Trial primary completion date: Feb 2016 --> Jun 2016
- Biomarker, Trial primary completion date: Markers of Response to Intravesical Bladder Cancer Therapy (clinicaltrials.gov) - Dec 5, 2015
P=N/A, N=300, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Feb 2016 --> Jun 2016 Trial primary completion date: Aug 2016 --> Aug 2017
- cisplatin / Generic mfg., gemcitabine / Generic mfg., sorafenib / Generic mfg.
Trial termination, Metastases: Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-na (clinicaltrials.gov) - Nov 16, 2015
P2, N=2, Terminated, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Aug 2016 --> Aug 2017 Completed --> Terminated; Lack of accrual
- Trial termination, Surgery, Metastases: Broccoli Sprout Extract in Treating Patients With Transitional Cell Bladder Cancer Undergoing Surgery (clinicaltrials.gov) - Nov 1, 2015
P=N/A, N=7, Terminated, Sponsor: Roswell Park Cancer Institute
Completed --> Terminated; Lack of accrual Active, not recruiting --> Terminated; low accrual
- Adstiladrin (nadofaragene firadenovec-vncg) / Ferring
Trial primary completion date: 1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder Cancer (clinicaltrials.gov) - Oct 22, 2015
P1b, N=9, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Terminated; low accrual Trial primary completion date: Jan 2016 --> Jan 2017
- |||| Neuvenge (lapuleucel-T) / Sanpower
Trial completion, Enrollment change, Trial primary completion date: DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma (clinicaltrials.gov) - Oct 7, 2015
P2, N=142, Completed, Sponsor: Dendreon
Trial primary completion date: Jan 2016 --> Jan 2017 Active, not recruiting --> Completed | N=180 --> 142 | Trial primary completion date: Jun 2016 --> Jul 2015
- cabazitaxel / Generic mfg.
Trial primary completion date: Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy (clinicaltrials.gov) - Oct 6, 2015
P2, N=33, Active, not recruiting, Sponsor: Thomas Jefferson University
Active, not recruiting --> Completed | N=180 --> 142 | Trial primary completion date: Jun 2016 --> Jul 2015 Trial primary completion date: Sep 2015 --> Dec 2015
- | sunitinib / Generic mfg.
Trial completion: Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer (clinicaltrials.gov) - Oct 6, 2015
P2, N=19, Completed, Sponsor: Case Comprehensive Cancer Center
Trial primary completion date: Sep 2015 --> Dec 2015 Active, not recruiting --> Completed
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion: Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer (clinicaltrials.gov) - Sep 14, 2015
P2, N=89, Completed, Sponsor: University of Michigan Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | sorafenib / Generic mfg.
Trial completion, Metastases: Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract (clinicaltrials.gov) - Sep 1, 2015
P2, N=17, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- vadimezan (ASA404) / Antisoma
Enrollment change, Trial withdrawal, Trial primary completion date: Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma (clinicaltrials.gov) - Aug 19, 2015
P2, N=0, Withdrawn, Sponsor: Hoosier Cancer Research Network
Active, not recruiting --> Completed N=40 --> 0 | Suspended --> Withdrawn | Trial primary completion date: May 2011 --> Jun 2010
- Trial completion, Trial primary completion date: Prostate Capsule Sparing Cystectomy and Nerve-sparing Radical Cystoprostatectomy in Men With Bladder Cancer (clinicaltrials.gov) - Aug 19, 2015
P2, N=40, Completed, Sponsor: University of Michigan
N=40 --> 0 | Suspended --> Withdrawn | Trial primary completion date: May 2011 --> Jun 2010 Active, not recruiting --> Completed | Trial primary completion date: Oct 2013 --> Aug 2014
- Adstiladrin (nadofaragene firadenovec-vncg) / Ferring
Trial primary completion date: Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer (clinicaltrials.gov) - Aug 13, 2015
P2, N=40, Active, not recruiting, Sponsor: FKD Therapies Oy
Active, not recruiting --> Completed | Trial primary completion date: Oct 2013 --> Aug 2014 Trial primary completion date: Mar 2015 --> Oct 2015
- valrubicin / Generic mfg.
Trial primary completion date: Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma (clinicaltrials.gov) - Aug 13, 2015
P1, N=4, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial primary completion date: Mar 2015 --> Oct 2015 Trial primary completion date: Sep 2015 --> Feb 2016
- | bortezomib / Generic mfg.
Trial completion, Metastases: Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter (clinicaltrials.gov) - Aug 9, 2015
P2, N=0, Completed, Sponsor: University Health Network, Toronto
Trial primary completion date: Sep 2015 --> Feb 2016 No longer recruiting --> Completed
- | Zarnestra (tipifarnib) / Kura Oncology
Trial completion: Tipifarnib in Treating Patients With Recurrent Bladder Cancer (clinicaltrials.gov) - Aug 9, 2015
P2, N=0, Completed, Sponsor: University Health Network, Toronto
No longer recruiting --> Completed No longer recruiting --> Completed
- apatorsen (OGX-427) / Achieve Life Sciences
Trial completion, Trial primary completion date, Combination therapy, Metastases: A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer (clinicaltrials.gov) - Jul 14, 2015
P2, N=182, Completed, Sponsor: OncoGenex Technologies
No longer recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Feb 2015 --> Oct 2014
- Calsed (amrubicin) / BMS, Nippon Kayaku
Enrollment change: Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma (clinicaltrials.gov) - Jul 13, 2015
P2, N=23, Active, not recruiting, Sponsor: Matthew Galsky
Active, not recruiting --> Completed | Trial primary completion date: Feb 2015 --> Oct 2014 N=35 --> 23
- NN1213 / Novo Nordisk
Trial completion, Enrollment change: High-Dose Multivitamins Compared to a Placebo in Preventing the Recurrence of Cancer in Patients With Early Stage Bladder Cancer (clinicaltrials.gov) - Jul 9, 2015
P3, N=21, Completed, Sponsor: Alliance for Clinical Trials in Oncology
N=35 --> 23 Active, not recruiting --> Completed | N=360 --> 21
- Javlor (vinflunine) / Pierre Fabre
Trial primary completion date, Metastases: VINSOR: Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract (clinicaltrials.gov) - Jun 29, 2015
P1, N=22, Recruiting, Sponsor: Dr Anders Ull
Active, not recruiting --> Completed | N=360 --> 21 Trial primary completion date: Jun 2013 --> Dec 2015
- Vectibix (panitumumab) / Amgen
Enrollment change, Trial primary completion date: PURO Panitumumab in Combination With Gemcitabine/Cisplatin in Advanced Urothelial Cancer (clinicaltrials.gov) - Jun 3, 2015
P2, N=2, Terminated, Sponsor: WiSP Wissenschaftlicher Service Pharma GmbH
Trial primary completion date: Jun 2013 --> Dec 2015 N=124 --> 2 | Trial primary completion date: Apr 2014 --> Mar 2012
- ||| Javlor (vinflunine) / Pierre Fabre
Trial completion, Trial primary completion date, Metastases: JONAS-1: JAVLOR (clinicaltrials.gov) - May 13, 2015
P=N/A, N=200, Completed, Sponsor: Pierre Fabre Pharma GmbH
N=124 --> 2 | Trial primary completion date: Apr 2014 --> Mar 2012 Active, not recruiting --> Completed | Trial primary completion date: Oct 2012 --> Sep 2011
- cabazitaxel / Generic mfg.
Trial completion, Enrollment change, Metastases: A Trial of Cabazitaxel for Advanced Transitional Cell Carcinoma (TCC) (clinicaltrials.gov) - May 12, 2015
P2, N=19, Completed, Sponsor: Rambam Health Care Campus
Active, not recruiting --> Completed | Trial primary completion date: Oct 2012 --> Sep 2011 Recruiting --> Completed | N=48 --> 19
- Trial primary completion date: A Laser Detection for Bladder Cancer by (Photodynamic) Spectra of Urine (clinicaltrials.gov) - May 1, 2015
P3, N=100, Recruiting, Sponsor: Princess Al-Johara Al-Ibrahim Cancer Research Center
Recruiting --> Completed | N=48 --> 19 Trial primary completion date: Apr 2015 --> Apr 2016
- lapatinib / Generic mfg., docetaxel / Generic mfg.
Trial primary completion date, Metastases: Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder (clinicaltrials.gov) - Apr 19, 2015
P2, N=15, Terminated, Sponsor: University of Southern California
Trial primary completion date: Apr 2015 --> Apr 2016 Trial primary completion date: Jul 2014 --> Dec 2015
- | Calsed (amrubicin) / BMS, Nippon Kayaku
Enrollment closed: Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma (clinicaltrials.gov) - Apr 8, 2015
P2, N=35, Active, not recruiting, Sponsor: Matthew Galsky
Trial primary completion date: Jul 2014 --> Dec 2015 Recruiting --> Active, not recruiting
- | Ibrance (palbociclib) / Pfizer
Enrollment open: Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy (clinicaltrials.gov) - Mar 27, 2015
P2, N=40, Recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- valrubicin / Generic mfg.
Enrollment closed, Enrollment change: Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma (clinicaltrials.gov) - Feb 19, 2015
P1, N=4, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=21 --> 4
- Zolinza (vorinostat) / Merck (MSD)
Enrollment change, Trial termination, Metastases: Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the Urothelium (clinicaltrials.gov) - Feb 13, 2015
P2, N=14, Terminated, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | N=21 --> 4 N=37 --> 14 | Completed --> Terminated; Trial stopped early for futility
- Votrient (pazopanib) / Novartis, BeiGene
Trial primary completion date, Metastases: Gemcitabine and Pazopanib in Chemotherapy Na (clinicaltrials.gov) - Feb 6, 2015
P2, N=45, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
N=37 --> 14 | Completed --> Terminated; Trial stopped early for futility Trial primary completion date: Jun 2014 --> Jun 2016
- INCB47986 / Incyte
Enrollment change, Trial termination, IO biomarker, Metastases: An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies (clinicaltrials.gov) - Feb 5, 2015
P1, N=5, Terminated, Sponsor: Incyte Corporation
Trial primary completion date: Jun 2014 --> Jun 2016 N=100 --> 5 | Active, not recruiting --> Terminated; Business decision.
- carboplatin / Generic mfg., paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Trial completion, Enrollment change, Metastases: Paclitaxel, Carboplatin and Gemcitabine in the Treatment of Patients With Advanced Transitional Cell Cancer of the Bladder (clinicaltrials.gov) - Jan 22, 2015
P2, N=68, Completed, Sponsor: University of Michigan Cancer Center
N=100 --> 5 | Active, not recruiting --> Terminated; Business decision. Active, not recruiting --> Completed | N=87 --> 68
- | Ibrance (palbociclib) / Pfizer
New P2 trial: Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy (clinicaltrials.gov) - Jan 8, 2015
P2, N=40, Not yet recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
- Preclinical: Diagnostic Accuracy of Optical Coherence Tomography in Upper Urinary Tract Urothelial Carcinoma (clinicaltrials.gov) - Dec 30, 2014
P=N/A, N=26, Completed, Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Leukine (sargramostim) / Partner Therap
Enrollment change, Trial termination, Trial primary completion date: Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy (clinicaltrials.gov) - Dec 24, 2014
P1, N=21, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=87 --> 68 N=42 --> 21 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2010 --> Dec 2009
- carotuximab IV (ENV-105) / Kairos Pharma
Trial primary completion date: TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma (clinicaltrials.gov) - Dec 19, 2014
P2, N=13, Completed, Sponsor: National Cancer Institute (NCI)
N=42 --> 21 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2010 --> Dec 2009 Trial primary completion date: Nov 2014 --> May 2014
- Biomarker, Trial primary completion date: Markers of Response to Intravesical Bladder Cancer Therapy (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=300, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Nov 2014 --> May 2014 Trial primary completion date: Aug 2015 --> Aug 2016
- cisplatin / Generic mfg., sirolimus / Generic mfg., gemcitabine / Generic mfg.
Trial primary completion date: Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer (clinicaltrials.gov) - Nov 19, 2014
P1/2, N=45, Recruiting, Sponsor: University of Washington
Trial primary completion date: Aug 2015 --> Aug 2016 Trial primary completion date: Oct 2014 --> Apr 2016
- carotuximab IV (ENV-105) / Kairos Pharma
Trial completion, Trial primary completion date: TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma (clinicaltrials.gov) - Nov 14, 2014
P2, N=13, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Oct 2014 --> Apr 2016 Active, not recruiting --> Completed | Trial primary completion date: Mar 2015 --> Nov 2014
- | sunitinib / Generic mfg.
Trial termination, Trial primary completion date, Metastases: Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma (clinicaltrials.gov) - Nov 13, 2014
P2, N=54, Terminated, Sponsor: University of Michigan Cancer Center
Active, not recruiting --> Completed | Trial primary completion date: Mar 2015 --> Nov 2014 Active, not recruiting --> Terminated | Trial primary completion date: Jun 2014 --> Dec 2011; Low accrual
- Calsed (amrubicin) / BMS, Nippon Kayaku
Trial primary completion date: Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma (clinicaltrials.gov) - Oct 30, 2014
P2, N=35, Recruiting, Sponsor: Matthew Galsky
Active, not recruiting --> Terminated | Trial primary completion date: Jun 2014 --> Dec 2011; Low accrual Trial primary completion date: Feb 2014 --> Jul 2014
- valrubicin / Generic mfg.
Enrollment change, Trial primary completion date: Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder (clinicaltrials.gov) - Oct 22, 2014
P3b, N=1, Terminated, Sponsor: Endo Pharmaceuticals
Trial primary completion date: Feb 2014 --> Jul 2014 N=60 --> 1 | Trial primary completion date: May 2013 --> Jan 2012